Model-Informed Drug Development

Business

Porsche's Electric Sports Car Ambitions Stall as Budget Pressures Mount

Under new CEO Michael Leiters, Porsche is reportedly considering axing its planned all-electric 718 Boxster and Cayman line. The potential move, driven by development hurdles and soaring costs, signals a strategic recalibration as the automaker grapples with a sales slowdown in China and the financial weight of revising its EV roadmap.

Feb 2, 2026

Business

Forrestania Resources Consolidates Control of High-Grade Mt Palmer Gold Project in Strategic $18m Deal

Forrestania Resources moves to 100% ownership of the historic Mt Palmer gold project in Western Australia through a share-based acquisition, aiming to fast-track development and feed its Lake Johnston processing facility.

Feb 2, 2026

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Barclays Bullish on 4D Molecular Therapeutics, Sees M&A and Pricing Trends as Key Catalysts

Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.

Feb 2, 2026

Business

Kura Oncology Eyes 2026 as Pivotal Year Amid Pipeline Expansion and Analyst Scrutiny

Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.

Feb 2, 2026

Business

Uber's Valuation Faces Near-Term Pressure Amid Autonomous Vehicle Uncertainty, BofA Says

BofA Securities has trimmed its price target for Uber Technologies, citing near-term uncertainties in the autonomous vehicle sector, even as the company launches a new internal data initiative aimed at accelerating AV development.

Feb 2, 2026

Business

Edwards Lifesciences Halts JenaValve Acquisition, Doubles Down on Core Valve Technology

Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.

Feb 2, 2026

World

UK's Gridworks Inks $400M Ethiopia Power Deals as Foreign Minister Visits to Address Migration Pressures

During UK Foreign Secretary Yvette Cooper's visit to Addis Ababa, British investor Gridworks signed landmark agreements to develop two major transmission projects. The deals, part of a broader UK strategy linking economic development with migration management, mark Ethiopia's first public-private partnerships in its power transmission sector.

Feb 2, 2026

Business

Carlsberg Exits Tibetan Brewery Venture, Ceding Full Control to Local Partner

Danish brewing giant Carlsberg has agreed to sell its 50% stake in the Lhasa Brewery joint venture to its local partner, Tibet Development, for 292 million yuan ($42 million), ending a partnership marked by operational disputes and significant financial impairments.

Feb 2, 2026

Business

Siemens Healthineers Bets on Irish Innovation with New €10 Million R&D Hub

The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.

Feb 2, 2026

FDA Rejects Aquestive's Oral Anaphylaxis Treatment, Leaving Patients Awaiting Epinephrine Alternative

The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.

Feb 2, 2026

Business

BeOne Medicines Deepens InSysBio Modeling Partnership to De-Risk Oncology Pipeline

BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.

Feb 2, 2026

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Feb 2, 2026

Business

VEON Doubles Down on Uzbekistan: Telecom Giant Opens New Cyber Hub and Launches AI Venture

VEON is deepening its investment in Uzbekistan's digital economy with a new network operations center for Beeline and the launch of BuildX, a software and AI development unit. The moves signal a strategic pivot from traditional telecom services towards higher-margin digital offerings in Central Asia.

Feb 2, 2026

Business

Agilysys Shares Tumble Despite Revenue Beat as Costs Dent Profits; Analysts Probe Growth Strategy

Hospitality tech provider Agilysys saw its stock price drop sharply post-earnings, even as Q4 revenue topped estimates. Higher development costs squeezed profits, though CEO highlighted strong subscription growth in key segments. Analysts are now scrutinizing the pace of major rollouts and efficiency gains.

Feb 2, 2026

Business

ABIVAX Shares Surge on Takeover Buzz and Pipeline Progress, Despite CEO Denials

ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.

Feb 2, 2026

Business

Beyond Humira: How AbbVie Plans to Reign as a Biopharma Powerhouse by 2031

With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.

Feb 2, 2026

World

Rafah Crossing Reopens Under Fragile Truce, Allowing First Limited Movement in Gaza

The vital Rafah border crossing between Gaza and Egypt has resumed operations for restricted humanitarian and civilian traffic, marking a critical, though tentative, development in the ongoing ceasefire agreement.

Feb 2, 2026

Business

GitLab's AI Ambitions Meet Market Skepticism as Analysts Sound Caution

GitLab's strategic pivot to become an AI-centric development platform is facing heightened scrutiny from Wall Street. Recent analyst downgrades, citing competitive pressures and execution risks, have cast a shadow over the company's transformation efforts, even as its stock struggles to recover from significant declines over the past year.

Feb 2, 2026

World

Costa Rica Elects Laura Fernandez, Vowing Constitutional Overhaul and Crime Crackdown

Laura Fernandez, a close ally of outgoing populist President Rodrigo Chaves, has been elected Costa Rica's next leader. She pledges to continue his transformative agenda, including constitutional reforms and emergency measures to combat drug violence, signaling a profound shift for the nation.

Feb 2, 2026